Daily Sepsis Research Analysis
Analyzed 79 papers and selected 3 impactful papers.
Summary
Three high-impact studies on sepsis span prevention, pathophysiology, and precision immunology: a large target-trial emulation shows GLP-1 receptor agonists reduce sepsis and hospitalization in non-obese type 2 diabetes; mechanistic work identifies adipose tissue lipolysis and circulating fatty acids as key mediators of infection tolerance with β3-adrenergic agonists showing survival associations; and an integrative Mendelian randomization implicates CD28-related T cell traits as mediators of neonatal bacterial sepsis risk.
Research Themes
- Metabolic tolerance and host-directed therapy in sepsis
- Antidiabetic agents and infection risk reduction
- Genetically informed immune mediators in neonatal sepsis
Selected Articles
1. Clinical effects of glucagon-like peptide-1 receptor agonist in type 2 diabetes with low body mass index: findings from large-scale emulated target trials.
In a large target trial emulation with 20,928 matched patients per arm, initiating GLP-1 receptor agonists (vs DPP-4 inhibitors) in adults with type 2 diabetes and BMI ≤30 kg/m² reduced major adverse kidney events and progression to dialysis, and also lowered hospitalization and sepsis risk, with neutral cardiovascular and mortality effects. Benefits were consistent across BMI strata and clinical subgroups.
Impact: Demonstrates infection-related benefits of GLP-1 therapy beyond glycemia and weight in a non-obese population, with large-scale, carefully emulated trial design and matched cohorts.
Clinical Implications: For adults with type 2 diabetes and BMI ≤30 kg/m², GLP-1 receptor agonists may confer kidney protection and reduce sepsis and hospitalization risk. While results are observational, they support considering GLP-1 RAs even in non-obese patients, pending prospective trials.
Key Findings
- After 1:1 propensity matching (n=20,928 per arm), GLP-1 RAs reduced MAKE (14.8% vs 16.8%; HR 0.93, p=0.005) and progression to dialysis (HR 0.78, p<0.001).
- GLP-1 RAs lowered hospitalization (HR 0.84, p<0.001) and sepsis risk (HR 0.88, p=0.001) versus DPP-4 inhibitors.
- Cardiovascular outcomes and all-cause mortality were similar between groups; benefits were consistent across BMI strata and subgroups.
Methodological Strengths
- Real-world target trial emulation with large TriNetX dataset and rigorous 1:1 propensity score matching.
- Consistent hazard ratio estimates across subgroups without evidence of effect modification.
Limitations
- Observational design with potential residual confounding and coding misclassification for sepsis outcomes.
- Medication adherence, dosing, and microbiological confirmation were not available.
Future Directions: Prospective randomized trials to validate infection- and kidney-related benefits of GLP-1 RAs in non-obese T2D; mechanistic studies linking GLP-1 signaling to host defense.
AIMS: Chronic kidney disease (CKD) is a common and serious complication of type 2 diabetes, yet the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in non-obese or mildly overweight individuals remains uncertain. This study evaluated renal, cardiovascular, and systemic outcomes associated with GLP-1 RA therapy in adults with type 2 diabetes and body mass index (BMI) ≤ 30 kg/m². MATERIALS AND METHODS: We conducted a real-world, target trial emulation, retrospective cohort study using the TriNetX US Collaborative Network. Adults with type 2 diabet
2. Lipid mobilization establishes metabolic tolerance and prevents autonomic collapse in infection.
This multi-system study identifies white adipose tissue lipolysis and circulating fatty acids as key mediators of metabolic tolerance to infection. Genetic ablation of adipose ATGL worsened sepsis survival by causing autonomic instability without altering pathogen burden, whereas restoring NEFAs or activating lipolysis via β3-agonists improved survival; higher NEFA levels in septic patients and β3-agonist exposure in EHR data associated with reduced mortality.
Impact: Proposes a paradigm of enhancing metabolic tolerance in sepsis via adipose lipolysis, supported by convergent evidence from human cohorts, mechanistic mouse models, and real-world EHR analyses, suggesting repurposing β3-agonists.
Clinical Implications: Circulating NEFAs may serve as prognostic markers of infection tolerance, and β3-adrenergic agonists could be repurposed to stabilize autonomic function and improve sepsis outcomes, pending randomized trials and safety evaluation.
Key Findings
- Higher circulating NEFA levels in septic patients were associated with reduced mortality.
- Adipose-specific ATGL deletion impaired lipolysis, caused hypothermia/bradycardia, and increased mortality without affecting pathogen burden, indicating a tolerance defect.
- Restoring NEFAs or pharmacologically activating lipolysis with a β3-adrenergic agonist improved survival in septic mice; EHR data linked β3-agonist exposure to lower mortality/hospice discharge.
Methodological Strengths
- Triangulation across human observational association, genetic and pharmacologic mouse models, and real-world EHR analyses.
- Mechanistic linkage of NEFAs to autonomic stability and survival, with rescue experiments.
Limitations
- Preprint status without peer review; clinical EHR associations remain susceptible to residual confounding.
- Optimal agent, dosing, and timing for β3-agonists were not established; external generalizability needs testing.
Future Directions: Conduct biomarker-guided randomized trials of β3-agonists in sepsis; define safety, dosing, and timing; validate NEFA-guided selection; explore interactions with nutritional/metabolic support.
UNLABELLED: Survival during infection depends on both pathogen clearance and the ability to tolerate infection-induced physiological changes. Metabolic adaptations are a central component of this tolerance, but the mechanisms underlying these responses remain incompletely defined. Here, we identify white adipose tissue (WAT) lipolysis as a central regulator of metabolic tolerance to infection. In patients with sepsis, higher circulating non-esterified fatty acid (NEFA) levels were associated with reduced mortality. In mouse models of polymicrobial sepsis, infection induced robust adipose lipol
3. Integrative Mendelian randomization reveals the mediating role of immune cell traits in the causal pathway from gene expression to neonatal bacterial sepsis.
An integrative two-step MR across eQTLGen, immune trait GWAS, and FinnGen NBS identified multiple gene-immune-mediating pathways, prominently implicating CD28-related T-cell phenotypes. The TRPM4 → CD28 on double-negative T cells → NBS chain showed the largest mediation (~40.5%), with supportive colocalization signals; reverse MR did not support feedback from NBS to immune traits.
Impact: Prioritizes specific, genetically informed immune phenotypes (CD28 axis) as mechanistic mediators and potential targets in neonatal sepsis, using a rigorous MR mediation framework with sensitivity and colocalization analyses.
Clinical Implications: Findings suggest that T-cell co-stimulation pathways (e.g., CD28-related traits) may be leveraged for risk stratification and mechanistic targeting in neonatal bacterial sepsis, pending neonatal-specific functional validation.
Key Findings
- Two-step MR identified 147 gene expressions and 23 immune traits associated with NBS after FDR correction.
- The TRPM4 → CD28 on double-negative T cells → NBS mediation path showed the largest mediation proportion (~40.54%) and remained directionally consistent across sensitivity tests.
- Colocalization supported shared variants for several signals (e.g., DBF4B, SNCA, SYCE1L); reverse MR did not support feedback from NBS to prioritized immune traits.
Methodological Strengths
- Integrative two-step MR mediation linking eQTLs, immune traits, and disease with multiple sensitivity analyses (MR-Egger, weighted median, heterogeneity).
- Use of colocalization to evaluate shared causal variants and reduce confounding from LD.
Limitations
- FinnGen NBS cases were few (n=203), which may limit power and increase uncertainty in mediation estimates.
- Assumptions of MR (no horizontal pleiotropy, correct instrument strength) may be violated; neonatal tissue- and cell-type–specific eQTLs were not directly assessed.
Future Directions: Validate prioritized immune mediators in neonatal cohorts using flow cytometry and functional assays; incorporate neonatal tissue-specific eQTL and single-cell omics; explore safe modulation of CD28-related pathways.
Neonatal bacterial sepsis (NBS) remains a major global burden. Although immune dysfunction is central to its pathogenesis, the causal contribution of specific immune cell phenotypes and their upstream genetic regulation is unclear. This study aimed to test whether genetically predicted gene expression influences NBS risk through immune cell traits using an integrative two-step Mendelian randomization (MR) mediation framework. We combined eQTLGen whole-blood expression quantitative trait loci (n ≈ 30,000), genome-wide association study of 731 immune traits (Sardinian cohort, n ≈ 3757), and FinnGe